High Purity Aphrodisiac Enhancer Ta Dalafil for Man (CAS:171596-29-5)
Chemical Information
Quick Details:
| Product Name | Ta Dalafil |
| Model No. | APH-1 |
| Appearance | White Powder |
| Suitable People | Adult |
| CAS No. | 171596-29-5 |
| Molecular Formula | C22H19N3O4 |
| Molecular Weight | 389.404 |
| Melting Point | 298-300°C |
| Product Specifications | Pharmaceutical Grade |
| Purity | 99%+ |
| Standard | Qualified |
| MOQ(Minimum Order Quantity) | 10g |
| Payment | L/C, T/T, Western Union |
| Shipment | EMS, DHL, FedEx, TNT |
| Packing | Foil Bag or as Required |
| Brand | Biocar |
| Origion | Hubei,China |
| Export Markets | Global |
Applications/Usage
Ta Dalafil is an oral medication used to treat erectile dysfunction (ED) in men. It may be taken only when sexual intercourse is anticipated, or at a lower dose daily, if regular sexual intercourse is expected. The drug is a phosphodiesterase type 5 inhibitor (PDE5 inhibitor). This class includes other drugs .
1. Ta Dalafilrelaxes muscles and increases blood flow to particular areas of the body.
2. Ta Dalafil is used to treat erectile dysfunction (impotence) and symptoms of benign prostatic hypertrophy (enlarged prostate). Another brand of Ta Dalafil is Adcirca, which is used to treat pulmonary arterial hypertension and improve exercise capacity in men and women.
3. Do not take while also taking Adcirca, unless your doctor tells you to.
4. Ta Dalafil can decrease blood flow to the optic nerve of the eye, causing sudden vision loss. This has occurred in a small number of people taking Ta Dalafil , most of whom also had heart disease, diabetes, high blood pressure, high cholesterol, or certain pre-existing eye problems, and in those who smoke or are over 50 years old.
5. This medicine is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
6. It is not known whether Ta Dalafil passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
7. Ta Dalafil is PDE5 inhibitor marketed in pill form for treating erectile dysfunction (ED) under the name , and under the name Adcirca for the treatment of pulmonary arterial hypertension. In October 2011 the U.S. Food and Drug Administration (FDA) approved for treating the signs and symptoms of benign prostatic hyperplasia (BPH) as well as a combination of BPH and erectile dysfunction (ED) when the conditions coincide. It initially was developed by the biotechnology company ICOS, and then again developed and marketed world-wide by Lilly ICOS, LLC, the joint venture of ICOS Corporation and Eli Lilly and Company. in 2.5 mg, 5 mg, 10 mg, and 20 mg doses, are yellow, film-coated, and almond-shaped. The approved dose for pulmonary arterial hypertension is 40 mg (two 20-mg tablets) once daily.
Dosage
Because of the different types of dosage form and specifications. please read carefully instructions or follow the doctor's advice.
Effcet
Erectile dysfunction, or impotence, affects many men and may be due to numerous factors, both physiological and psychological. The physiological process of attaining and maintaining an erection is a complex one and involves various chemicals and nervous system signals. Cyclic GMP is one of the chemical messengers involved. When sexual stimulation occurs, cGMP is released and it causes dilatation of the blood vessels in the penis, allowing more blood to flow into it and causing it to become rigid.